GlassScriptPhysician profile
Salima Qamruddin
NPI 1659581536
$27,333.73
in general payments reported to CMS, 2019-2025
14 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $8,911 · 2021: $2,933 · 2022: $86.47 · 2023: $417 · 2024: $217 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $2,155 · Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Travel and Lodging | $2,155.01 |
| Food and Beverage | $1,248.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24,487.00 | 2020-2025 | |
| Edwards Lifesciences Corporation | $1,723.42 | 2025 | Evoque |
| Janssen Pharmaceuticals, INC | $348.46 | 2020-2023 | Xarelto |
| Amgen INC. | $157.11 | 2021-2024 | Repatha |
| Medtronic, INC. | $104.59 | 2023 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $96.23 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.53 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $78.20 | 2022-2025 | Eliquis |
| Siemens Medical Solutions USA, INC. | $66.26 | 2024 | Acuson Sequoia Diagnostic Ultrasound System, Acuson Freestyle Diagnostic Ultrasound System, Acuson Origin Diagnostic Ultrasound System |
| Pfizer INC. | $53.64 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $46.49 | 2021-2023 | Farxiga, Andexxa |
| Lantheus Medical Imaging, INC. | $43.59 | 2023-2024 | Definity |
| Abbott Laboratories | $19.69 | 2025 | Triclip |
| Astellas Pharma US INC | $17.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salima Qamruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.